SYNthesis med chem opens new facility in Cambridge
pharmafile | September 9, 2013 | News story | Research and Development, Sales and Marketing |Â Â Cambridge, China, SYNthesis med chemÂ
Contract research organisation SYNthesis med chem has announced that it has joined the bio-medical cluster by opening a new facility at the Babraham Research Campus in Cambridge, UK.
SYNthesis combines its medicinal chemistry expertise located at the company’s labs in Melbourne, Australia and now Cambridge, with synthetic chemistry provided by the firm’s chemists in Shanghai, China.
It says the opening of this new facility in Cambridge will enable SYNthesis to add UK-based medicinal chemistry expertise to the organisation, and to provide European customers with local project management for synthetic and medicinal chemistry projects.
Professor Andrew Wilks, co-founder and executive chairman of SYNthesis, said: “With an increasing customer base across Europe it was essential that we put in place the infrastructure and resources to deliver the required levels of support for all our medicinal and synthetic chemistry projects. The new Cambridge facility does that, but also gives us the capacity to grow as we attract new customers.”
Dr Xian Bu, co-founder and managing director of SYNthesis added: “In addition to establishing this new office and labs in Cambridge UK we will be announcing plans for our operations in China later this year.”
Derek Jones of the Babraham Research Campus said they are delighted that SYNthesis has chosen its research campus as the home for their European operations, and that they welcome them to the heart of the Cambridge bio-medical cluster.
Brett Wells
Related Content
Addenbrooke’s hospital offers first self-service digital eye test
Addenbrooke’s Hospital, Cambridge, has become the first in the UK to deploy a digital self-testing …
CARBOGEN AMCIS manufacturing license advances services in China
Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has …
NDA in China receives priority review status for lung cancer treatment
HUTCHMED have announced that the China National Medical Products Administration (NMPA) have granted a priority …
